Optimising oral PrEP while awaiting long-acting cabotegravir

Lancet HIV. 2023 Nov;10(11):e694-e695. doi: 10.1016/S2352-3018(23)00231-X. Epub 2023 Sep 29.

Authors

Sheena McCormack¹, Mackenzie Leigh Cottrell²

Affiliations

¹ MRC Clinical Trials Unit at University College London, Institute of Clinical trials and Methodology, London, UK. Electronic address: s.mccormack@ucl.ac.uk.
² Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.

PMID: 37783220
DOI: 10.1016/S2352-3018(23)00231-X

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Pre-Exposure Prophylaxis*
Pyridones / therapeutic use

Substances

cabotegravir
Anti-HIV Agents
Pyridones

Grants and funding